Afrezza Inhaled Insulin and Lung Safety: Why Spirometry Is Essential Before Starting
By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad
Afrezza is a rapid-acting human insulin powder inhaled through a special device to help control blood sugar around meals. For some adults, it offers an alternative to repeated mealtime injections. But before starting Afrezza, an important question must be answered: Are your lungs suitable for inhaled insulin?
Key message: Afrezza is contraindicated in chronic lung disease such as asthma and COPD. The current U.S. prescribing information recommends a lung-function assessment using spirometry (FEV1) before treatment, after six months and annually thereafter, even if you do not feel breathless.
What is Afrezza inhaled insulin?
Afrezza is dry-powder human insulin supplied in single-use cartridges and inhaled at the beginning of a meal. It is absorbed through the lungs and acts quickly on meal-related glucose rises. It is not an oral tablet, an asthma inhaler or a replacement for all types of insulin.
People with type 1 diabetes still require basal insulin alongside Afrezza. Inhaled Afrezza is not recommended to treat diabetic ketoacidosis (DKA). For an introduction to the medicine, see our Afrezza and mealtime injections guide.
Is Afrezza available in India in 2026?
Yes. Cipla announced its commercial launch in India on 22 December 2025, following CDSCO approval for distribution and marketing. The Indian approval announced by Cipla and MannKind was for adult patients with diabetes. Local pricing and stock vary by pharmacy.
The U.S. label was updated in May 2026 and includes adults and children aged six years and older, but the U.S. age indication must not be assumed to apply in India. Prescribing here should follow the current India-approved product information.
Why must lung health be assessed before Afrezza?
Afrezza acts through the lungs, and in some people it can trigger bronchospasm—a sudden narrowing of the airways that can cause wheezing or severe breathing difficulty. Its U.S. product label carries a boxed warning for acute bronchospasm in patients with chronic lung disease.
The product may also cause changes in measured lung function over time. For this reason, a patient’s medical history and symptoms alone are not enough: baseline spirometry helps establish a measurement for comparison during treatment.
Important: A normal spirometry reading does not make Afrezza appropriate for someone with established asthma or COPD; these conditions remain contraindications.
What is a spirometry test, and what does FEV1 mean?
Spirometry is a non-invasive test of breathing. You take a deep breath and exhale forcefully into a mouthpiece while a machine measures airflow. One important result is FEV1 (forced expiratory volume in one second), the volume of air expelled in the first second of a forced exhalation.
Your clinician interprets FEV1 together with other lung-function results, your medical history and symptoms. A baseline measurement is essential so that any subsequent change can be identified.
Afrezza lung-function monitoring schedule
| Timing | What to do | Purpose |
|---|---|---|
| Before starting | Review respiratory history, examine the patient and perform spirometry including FEV1 | Identify lung disease and establish baseline function |
| After 6 months | Repeat spirometry and discuss respiratory symptoms | Compare with baseline |
| Every year | Repeat lung-function assessment even without symptoms | Monitor longer-term change |
| Earlier when symptoms occur | Clinical review and potentially additional testing | Investigate cough, wheezing or breathlessness |
The current U.S. prescribing information states that clinicians should consider discontinuing Afrezza if FEV1 declines by 20% or more from baseline. Any decision about changing insulin should include a safe alternative treatment plan and glucose monitoring. Never stop insulin independently.
Who should avoid Afrezza?
- People with asthma or COPD: Afrezza is contraindicated because of the risk of acute bronchospasm.
- People currently experiencing hypoglycaemia: do not administer insulin during an active low-glucose episode.
- People with serious hypersensitivity to human insulin or ingredients in the product.
- Current smokers or recent quitters: Afrezza is not recommended because adequate safety and effectiveness information is unavailable for these groups.
- People with DKA: Afrezza is not intended for diabetic ketoacidosis treatment.
People with a history of lung cancer, recurrent respiratory symptoms or other significant lung conditions require careful specialist assessment. Tell the prescriber about prior asthma diagnoses, wheezing, smoking, vaping, respiratory infections and inhaler use.
Which side effects should patients watch for?
Low blood sugar (hypoglycaemia) remains an important risk with any insulin. A cough can also occur with Afrezza. Other important risks include acute bronchospasm, a decline in lung function, allergic reactions and low blood potassium.
Contact your healthcare professional about a new or persistent cough, and seek urgent medical care for significant wheezing, sudden breathing difficulty, chest tightness or signs of a severe allergic reaction.
Low-glucose symptoms may include sweating, trembling, hunger, dizziness or confusion. Follow your prescribed hypoglycaemia plan and seek emergency care for seizures, severe confusion or inability to swallow.
Does Afrezza replace NovoRapid or Humalog unit for unit?
No. Afrezza uses single-use cartridges, with the U.S. formulation available in 4-, 8- and 12-unit strengths. The labelled units are not interchangeable unit for unit with injected mealtime insulin doses. A clinician must determine the starting dose and subsequent titration using glucose readings, meal patterns and individual insulin needs.
In people with type 1 diabetes, basal insulin continues to be essential. Read our separate guide to switching from NovoRapid or Humalog to Afrezza for a more detailed discussion of clinician-supervised transition.
Five questions to ask before starting Afrezza
- Is mealtime insulin appropriate for my diabetes plan? Not everyone with type 2 diabetes needs mealtime insulin.
- Are my lungs suitable? Discuss your respiratory diagnoses, smoking history and any cough or wheezing.
- Have I completed baseline spirometry? Make sure the FEV1 result is documented.
- Do I understand the cartridge and glucose-monitoring plan? Ask for inhaler training and instructions on when to check glucose.
- How will follow-up work? Plan the six-month and annual lung tests, as well as diabetes reviews and a contact plan for concerning symptoms.
Frequently asked questions
Can I start Afrezza without a lung test if I breathe normally?
No. The U.S. label recommends a history, examination and baseline spirometry for all patients before initiation, even when they have no breathing symptoms.
Can someone with childhood asthma use Afrezza if spirometry is normal?
A past or current asthma diagnosis requires careful review, and Afrezza is contraindicated in patients with chronic lung disease such as asthma. Do not assume that a normal test removes this contraindication.
Will Afrezza permanently damage my lungs?
Not everyone experiences a significant change in lung function. Clinical studies detected modest average differences in FEV1, but long-term effects require careful consideration and monitoring. The individual risks and benefits should be discussed with the treating clinician.
Does a new cough mean I must stop Afrezza immediately?
Not every cough has the same cause, but a new, persistent or recurring cough warrants prompt review and possibly repeat testing. Significant wheezing or breathing difficulty requires urgent assessment.
Is Afrezza completely injection-free for type 1 diabetes?
No. Afrezza may replace some mealtime injections in eligible patients but does not replace basal insulin, which may still be delivered through injection or pump therapy.
Does Afrezza need to be taken at every meal?
Any dosing schedule should follow the individualized prescription and current local product information. Do not add, omit or double insulin doses without your clinician’s guidance.
Afrezza insulin consultation in Ahmedabad
Modern diabetes care considers not only blood-glucose targets but also safety, daily routines and treatment preferences. Dr. Moxit Shah, DM Endocrinology, at Vishuddha Diabetes, Thyroid, Weight Loss Clinic provides individualized diabetes management and assessment of modern insulin-treatment options.
Vishuddha Diabetes, Thyroid, Weight Loss Clinic
104–105, Elite Magnum, Bhuyangdev Cross Road, Opp. Utsav Elegance, Vardhmannagar Society, Ghatlodiya, Memnagar, Ahmedabad, Gujarat 380061, India
Appointments: +91 99799 92797
Medical references
- Afrezza U.S. prescribing information, updated May 2026 (DailyMed).
- Cipla: Afrezza launched in India, December 2025.
- MannKind: CDSCO adult approval in India, December 2024.
Medical disclaimer: This article is for general education, not an insulin prescription. Indian-approved product instructions may differ from current U.S. labeling. Do not start, stop or change prescribed insulin without medical supervision.
